My Clinical Trials Diary

The global e-clinical solution software market is witnessing significant growth due to increasing clinical trials and R&D investments in pharmaceuticals and life science sectors. Increasing prevalence of diseases across the world is leading to rise in number of clinical trials.  Various lifestyle-associated diseases and genetic disorders in the Middle East and North Africa have also led to increase in clinical trials in the respective regions. In addition, the pharmaceutical industry is facing immense pressure to reduce the time consumed to conduct clinical trials and increase effect of drugs.  Presence of various end users such as pharmaceuticals, clinical research organizations (CROs), and healthcare providers has increased the demand for e-clinical solution software. The global e-clinical solution software market was valued at US$ 3,005 Mn in 2014 and is expected to expand at a CAGR of 13.8% from 2014 to 2020 to reach US$ 6,515.3 Mn by 2020. Continue reading here . ᐧ

ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance ( link ) Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in  Boston . These findings suggest that ADI-PEG 20 could potentially enhance the activity of anti-tumor immune therapies, including checkpoint inhibitors. ᐧ

The gist of a panel discussion organized by NKP Salve Institute of Medical Sciences (NKPSIMS) on the occasion of World Bioethics Day on Wednesday suggested that any doctor or hospital cannot take for granted patient's consent while giving treatment or doing any procedure. Doctors have to ensure that the patient is well informed about the treatment being given, its pros and cons, and that there is no violation of his human rights, dignity, privacy and confidentiality. Continue reading here . ᐧ

It may take a great deal of patience and time to confirm asthma when a child is rushed to a clinic with breathing complication or coughing fits for it involves taking an x-ray and then getting the toddler to breathe through a mouthpiece of a device. But a tiny strip can soon do that job saving valuable time and letting a physician begin treatment right away. A team of researchers at VIT University has developed the strip that allows doctors to conduct a non-invasive breath test and get results within a matter of seconds. The white strip would turn blue when an asthmatic breathes over it. The strip, which has been tested in laboratories, will soon undergo clinical trials before it hits the market. Continue reading here. ᐧ

Clinical trials for Ayurveda-based drug for dengue, jointly being carried out by the Indian Council of Medical Research and the Ministry of AYUSH, are in the "advanced stages" and presently its clinical safety and efficacy is being tested, senior officials today said. Central Council for Research in Ayurvedic Sciences (CCRAS), an autonomous body under the Ministry of AYUSH and ICMRs regional research centre in Belgaum in Karnataka are carrying out the trials. "Clinical trials on dengue drug are in advanced stages. CCRAS and ICMR are conducting it in Belgaum to test the clinical safety and efficacy. The drug had earlier been standarised and after we got positive leads on it last year, we decided to go for the trials," Joint Secretary, AYUSH Ministry, A K Ganeriwala, said. Continue reading here . ᐧ